George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVela Technologies Regulatory News (VELA)

Share Price Information for Vela Technologies (VELA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.012
Bid: 0.011
Ask: 0.013
Change: 0.00 (0.00%)
Spread: 0.002 (18.182%)
Open: 0.012
High: 0.012
Low: 0.012
Prev. Close: 0.012
VELA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re. Economic Interest in AZD1656

21 Sep 2023 09:01

RNS Number : 2155N
Vela Technologies PLC
21 September 2023
 

21 September 2023

Vela Technologies plc

("Vela" or "the Company")

 

Update on Put Option for potential sale of Economic Interest in AZD1656

Further to the Company's announcements on 15 August 2023, 7 September 2023 and 8 September 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made by Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy") that at the special meeting of stockholders held yesterday, its initial business combination with Conduit Pharmaceuticals Limited ("Conduit") has been approved.

 

An extract of the Murphy announcement is set out below and a link to the announcement can be found here:

 

https://www.accesswire.com/786091/murphy-canyon-acquisition-corp-announces-stockholder-approval-of-the-proposed-combination-with-conduit-pharmaceuticals-limited

 

On 20 April 2023, Vela announced that the Company entered into a put option agreement to give the Company the right, but not the obligation ("the Option"), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of £4.0 million. The Option was granted by Conduit and its prospective parent company, Murphy, a Company listed on NASDAQ.

 

On 15 May 2023, Vela announced that Murphy had filed the Form S-4 Registration Statement and preliminary proxy statement with the SEC.

 

Following the approval of the business combination of Conduit and Murphy by Murphy shareholders, the Board of Vela intends to exercise the Option following the satisfaction or waiver of the remaining closing conditions as stated in the Murphy announcement.

 

The Company will release further announcements as and when appropriate.

 

Extract from Murphy announcement

 

SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (Nasdaq:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company will operate as Conduit Pharmaceuticals Inc. and its common stock and public warrants will trade on The Nasdaq Global Market under the symbols "CDT" and "CDTTW". Assuming that closing is completed on September 21, 2023, trading in the common stock and public warrants is expected to continue on Nasdaq, switching from the symbols "MURF" and "MURFW" to the new symbols "CDT" and "CDTTW", respectively, at the open of trading on September 22, 2023.

 

About Conduit

 

Conduit is a disease agnostic life science company providing an efficient model for compound development. Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and was established to fund the development of clinical molecules licensed from major pharmaceutical companies.

 

About Murphy Canyon Acquisition Corp.

 

Murphy Canyon is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Management is led by Jack Heilbron, Chief Executive Officer and Chairman of the Board of Directors. Murphy Canyon is sponsored by Murphy Canyon Acquisition Sponsor, LLC, a wholly owned subsidiary of Presidio Property Trust, Inc. (Nasdaq: SQFT), which is expected to own 4,015,250 shares of Conduit after the successful completion of the Business Combination.

 

Important Information and Where to Find It

 

This press release relates to a proposed transaction between Conduit and MURF. In connection with the proposed Business Combination, Murphy Canyon filed its registration statement on Form S-4 that includes a proxy statement with respect to the stockholder meeting of Murphy Canyon and a prospectus with respect to securities of the combined company (the "Registration Statement"). The proxy statement/prospectus was sent to all Murphy Canyon stockholders. Murphy Canyon has also filed prospectus supplements amending the proxy statement/prospectus that was sent to all Murphy Canyon stockholders. Murphy Canyon has filed and will file other documents regarding the proposed Business Combination with the U.S. Securities and Exchange Commission (the "SEC"). INVESTORS AND SECURITIES HOLDERS OF MURPHY CANYON ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, PROSPECTUS SUPPLEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.

 

Investors and securities holders are able to obtain free copies of the Registration Statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Murphy Canyon through the website maintained by the SEC at https://sec.gov/. In addition, the documents filed by Murphy Canyon may be obtained free of charge from Murphy Canyon's website at https://murphycanyonac.com or by written request to info@murphycanyonac.com. Additional information about the business combination agreement dated November 8, 2022, as amended (the "Business Combination Agreement"), and the transactions contemplated thereby (the "Transaction") and investor presentations, were provided in Current Reports on Form 8-K filed by Murphy Canyon with the SEC which can be accessed at www.sec.gov as well as online at https://murphycanyonac.com.

 

 

 

For further information, please contact:

Vela Technologies plc

Brent Fitzpatrick, Non-Executive Chairman

James Normand, Executive Director

Tel: +44 (0) 7410 886830

 

Allenby Capital Limited (Nominated Adviser)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Piers Shimwell

Peterhouse Capital Limited (Broker)

Tel: +44 (0) 20 7469 0930

Lucy Williams / Duncan Vasey

Novus Communications (PR and IR Adviser)

Tel: +44 (0) 20 7448 9839

Alan Green / Jacqueline Briscoe

 

About Vela Technologies

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGRGDCRUDDGXB
Date   Source Headline
26th Mar 20247:00 amRNSIssue of Equity
26th Feb 20241:21 pmRNSHolding in Company
23rd Feb 202412:15 pmRNSQuarterly Investment Update
8th Jan 202411:49 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSInterim Results
13th Dec 20237:00 amRNSQuarterly Investment Update
11th Dec 20232:19 pmRNSResult of AGM
5th Dec 202311:04 amRNSHolding in Company
1st Dec 20233:02 pmRNSExercise of Put Option
17th Nov 20238:58 amRNSNotice of AGM
28th Sep 20237:00 amRNSFinal results for the year ended 31 March 2023
27th Sep 20237:00 amRNSQuarterly Investment Update
21st Sep 20239:01 amRNSUpdate re. Economic Interest in AZD1656
8th Sep 20233:18 pmRNSFurther update re. Economic Interest in AZD1656
7th Sep 20237:00 amRNSUpdate re. Economic Interest in AZD1656
5th Sep 20238:50 amRNSUpdate on investment in Tribe Technology Group
15th Aug 20237:00 amRNSUpdate re. Economic Interest in AZD1656
12th Jun 202311:11 amRNSHolding in Company
6th Jun 20237:00 amRNSQuarterly Investment Update
23rd May 202311:45 amRNSInvestment in Tribe Technology Group Limited
15th May 20231:23 pmRNSUpdate re. Economic Interest in AZD1656
20th Apr 20233:01 pmRNSOption for potential sale of interest in AZD1656
14th Mar 20232:57 pmRNSInvestment in EnSilica plc
10th Feb 20237:00 amRNSQuarterly Investment Update
20th Jan 202312:27 pmRNSInvestment in Ethernity Networks Ltd
15th Dec 20227:00 amRNSInterim Results
6th Dec 20227:00 amRNSUpdate re. investment in EnSilica
28th Nov 20227:00 amRNSFurther investment in Northcoders Group plc
9th Nov 20229:00 amRNSUpdate re. AZD1656
8th Nov 20227:00 amRNSQuarterly Investment Update
25th Oct 202212:49 pmRNSResult of AGM
20th Oct 20221:52 pmRNSHolding(s) in Company
20th Oct 20227:52 amRNSBoard Change
28th Sep 20227:00 amRNSFinal results for the year ended 31 March 2022
2nd Sep 20227:40 amRNSStrategic Update
18th Aug 20229:53 amRNSUpdate re. St George Street Capital COVID-19 trial
22nd Jul 20227:00 amRNSQuarterly Investment Update
21st Jul 20221:40 pmRNSAppointment of Non-Executive Director
11th Jul 20227:00 amRNSHolding in Company
6th Jul 202212:07 pmRNSUpdate on investment - Community Social Investment
1st Jul 20221:27 pmRNSHolding(s) in Company
23rd Jun 202212:28 pmRNSInvestment in TruSpine Technologies plc
14th Jun 202212:49 pmRNSFurther update re TruSpine Technologies plc
14th Jun 20227:00 amRNSStatement re. potential investment in TruSpine
19th May 20221:26 pmRNSUpdate re. investment in EnSilica
3rd May 20227:00 amRNSQuarterly Investment Update and Change of Broker
26th Apr 20227:00 amRNSAppointment of PR and IR Adviser
30th Mar 20221:15 pmRNSAcquisition of a 28.8% interest in Igraine plc
7th Mar 20227:15 amRNSUpdate re. St George Street Capital COVID-19 trial
8th Feb 20221:30 pmRNSTR-1:Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.